Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Ann Surg. 2012 Oct;256(4):560–572. doi: 10.1097/SLA.0b013e31826a9064

FIGURE 3. SDF-1α activation of BMDSC promotes diabetic wound healing and re-epitheliazation.

FIGURE 3

A: Wound healing rate expressed as percent recovery. Two groups of Type 2 diabetic Leprdb/db mice were wounded and treated with SDF-1α Primed diabetic BMDSC versus control (BSA) diabetic BMDSC. Wounds were followed and analyzed using digital photography and Image J software. Diabetic wounds treated with SDF-1α activated cells had significantly faster wound closure rates starting from POD 9 when compared to diabetic wounds treated with control BMDSC. B: Representative images of wounds at different time points are shown for both groups. C: Representative hematoxylin/eosin-stained paraffin sections from 21-day wounds treated with control BMDSC versus SDF1-α activated BMDSC (5 × magnification). Black arrows indicate total wound area and point to the epithelial layer of normal skin immediately lateral to the wound edge. White arrows depict the area of complete re-epitheliazation in wound treated with SDF-1α Primed BMDSC.